Swiss drug giant Novartis is ending its trial of malaria drug hydroxychloroquine against Covid-19 after failing to find enough participants, it said on Friday.
This content was published on
2 minutes
Keystone-SDA/Reuters/sb
Basel-based Novartis began the clinical trial in April. Some 440 hospitalised patients with the virus were expected to participate in the study.
But the pharma company said on June 19External link that it had decided to halt the trial due to “acute enrolment challenges that have made trial completion infeasible”.
Novartis’ move follows this week’s US Food and Drug Administration’s (FDA) decision to revoke emergency use authorisation for hydroxychloroquine against Covid-19 on grounds it and a related drug, chloroquine, are unlikely to help patients.
Hydroxychloroquine, also used to treat inflammatory disorders including rheumatoid arthritis and lupus, has been caught in a political debate as US President Donald Trump promoted it, even though there was no scientific evidence that it helps against the new coronavirus.
Several studies of the decades-old malaria drug including in Britain were recently halted after scientists concluded it was “useless” against COVID-19. Last week the World Health Organization halted the hydroxychloroquine arm of one of its trials.
“The recruitment challenge facing our hydroxychloroquine trial has made it unlikely that the clinical team will be able to collect meaningful data in a reasonable time frame to determine the efficacy of hydroxychloroquine in treating patients with COVID-19,” Novartis said.
The pharmaceutical company said its study, so far, raised no safety issues and drew no conclusions about hydroxychloroquine’s efficacy.
Novartis had donated up to 130 million doses of hydroxychloroquine, including millions in the United States, and Chief Executive Vas Narasimhan two months ago claimed the drug was the company’s biggest hope against the new coronavirus.
Swiss football boss wants crackdown on individual hooligans
This content was published on
The head of the Swiss Football League says he prefers a harsher approach to individual hooligans rather than collective punishment measures affecting all fans.
Amherd: Council of Europe is ‘as urgently needed as ever’
This content was published on
The Swiss government emphasised on Sunday the vital role of the Strasbourg-based Council of Europe, 75 years after it was founded.
Swiss minister: Italy will back Switzerland in EU talks
This content was published on
Bern can count on the backing of Italy as it re-enters talks with the European Union on future relations, Viola Amherd says.
Student protestors at University of Lausanne continue pro-Palestine sit-in
This content was published on
Since Thursday, a hall on campus has been occupied by students calling for a boycott of Israeli academic institutions and a ceasefire in Gaza.
This content was published on
Swiss public broadcasters RTS and SRF are drastically reducing their communications via the social network X (formerly Twitter).
Israel: president of Swiss universities rejects academic boycott
This content was published on
Luciana Vaccaro, president of Swissuniversities, the umbrella group of Swiss universities, is not in favour of an academic boycott of Israeli universities.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Covid-19 is both threat and opportunity for Swiss biotech
This content was published on
Although the coronavirus pandemic is the Swiss biotech industry’s time to shine, it has left many smaller firms struggling to survive.
Hydroxychloroquine study withdrawn over data concerns
This content was published on
Authors have withdrawn an influential article finding that hydroxychloroquine had no benefit against Covid-19, citing data concerns.
Novartis CEO warns that data on Covid-19 drugs is missing
This content was published on
Potential pharmaceutical solutions to combat Covid-19 must have strong clinical data to back their efficacy, according to Novartis boss Vasant Narasimhan.
‘Anti-malaria drug can kill coronavirus’: Novartis chief
This content was published on
Swiss pharmaceutical giant Novartis believes the anti-malaria drug hydroxychloroquine offers one of the best hopes to combat coronavirus.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.